Endo International (NASDAQ:ENDP)
has been very acquisitive over the past couple of years, using deals to
not only leverage its tax-advantaged Irish domicile but bulk up what I
believe is an underrated generics business. Tuesday's announcement of an
offer to buy Auxilium (NASDAQ:AUXL)
makes quite a bit of sense; not only is their potential tax leverage
here, but Endo's strong legacy position in urology could improve uptake
of Auxilium's key drug Xiaflex and recharge Endo's branded drug
business.
Continue reading here:
Endo's Bid For Auxilium Makes Sense
No comments:
Post a Comment